Patrick Campbell

Results from a recent study suggest that greater cumulative exposure to estrogen throughout a woman’s lifespan could increase her risk of stroke.

Milvexian at doses of 25 mg to 100 mg twice daily showed an approximate 30% relative risk reduction of ischemic stroke compared with placebo.

The Alnylam Pharmaceuticals agent, already approved for the treatment of polyneuropathy in those with hATTR amyloidosis, has now shown promise as a therapeutic option for patients with ATTR amyloidosis with cardiomyopathy.

Those with an optimal Life's Simple 7 score had roughly a 30% to 43% lower lifetime stroke risk than those with an inadequate Life's Simple 7 categorization, corresponding to almost 6 additional years of stroke-free life.

Those with the common thyroid disorder displayed a more than 80% increased risk of dementia, with a more than 3-fold increase in the risk among those requiring hormone replacement therapy.

The new ASA/AHA guidance, updating the prior 2015 publication, provides several significant recommendations and changes, including those for the use of antiseizure medications in patients with ICH.

Findings of the Salt Substitute and Stroke Study suggest a switch to salt substitute could reduce the risk of stroke by 13% in those with a history of hypertension or stroke.

Patients who had a mobile stroke unit dispatched had lower 3-month coprimary disability score.

Data from more than 37k patients in the UK Biobank study suggests hypertension in midlife was linked to an increased risk of white matter hyperintensities later in life.

An analysis from English and Scottish stroke centers provides physicians a new view of the trends and outcomes of patients with COVID-19 who experience stroke.

The composite primary end point of the study occurred in 9.6% of patients in the lower-target LDL-C group compared with 12.9% in the higher target group.

The beneficial impact on stroke risk appeared to be greater in patients age 79 and younger than in the older patients examined.